KiOmed Pharma Entered into a License Agreement with Hansoh Pharma to Develop and Commercialize KiOmedinevsOne for Knee Osteoarthritis
Shots:
- KiOmed to receive an up front, ~$63.62M in development, regulatory & commercial milestones along with royalties. The companies collaborated to develop & commercialize KiOmedinevsOne for knee osteoarthritis, in China’s mainland, Macau & Taiwan
- Hansoh to get an exclusive right & will be responsible to develop & commercialize KiOmedinevsOne & its future extensions in the territory while KiOmed obtains the right for KiOmedinevsOne in all other markets globally
- KiOmedinevsOne is a carboxymethyl chitosan inj. & has been launched in the EU in 2021. In clinical studies, significant pain reduction within 2wks., following a single inj. of KiOmedinevsOne & 66% in WOMAC pain score with a long-lasting osteoarthritis symptom reduction for 6mos.
Ref: Businesswire | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
